Business Wire

CA-AVIATRIX

9.3.2021 15:02:11 CET | Business Wire | Press release

Share
2021 Total Economic Impact™ Study of the Aviatrix Cloud Network Platform Shows 222% ROI

Aviatrix , the cloud network platform, today announced the availability of the 2021 Forrester's Total Economic Impact™ (TEI) Study commissioned by Aviatrix, conducted independently by Forrester Consulting in January 2021. The TEI Study is based on Forrester's in-depth interviews with Aviatrix customers and provides a quantitative, business value justification designed to help IT leaders. It demonstrates a composite cost-savings and business benefits analysis interviewed customers realized by leveraging the Aviatrix cloud network platform and provides a model for determining economic value in any organization.

The complete results of the TEI Study of Aviatrix can be found and downloaded here , where readers will learn how Aviatrix customers leverage more advanced cloud networking, security, and operational visibility for their cloud and multi-cloud network environments, helping them generate new revenue and ensure operational efficiency at significantly lower costs.

Key highlights of the TEI Study on Aviatrix cloud network platform Include:

  • Aviatrix pays for itself more than 2x in the span of three years (222% ROI)
  • Over $3 million in revenue and margin gains from new and existing customers attributed to multi-cloud readiness and faster time-to-market
  • Over $1 million in cost savings from operational efficiency and resource re-allocation
  • Over $4 million in business benefits and cost savings over three years

Cloud infrastructure is becoming the norm for many organizations. Decision makers may plan to focus on a single cloud platform, but they often need to support many due to acquisitions, client requirements, or app developer preferences. Each cloud service provider comes with its own processes, native constructs and tools that can slow cloud network operations. The Aviatrix cloud network platform helps organizations automate and control cloud network infrastructure, maintain security compliance, and respond to clients much faster.

Aviatrix customers saw significant benefits after deploying the company’s cloud network platform:

  • “Without Aviatrix, it would have taken an extra year and twice the staff” Sr. Infrastructure Architect, insurance company.
  • “We have been able to open new lines of business and keep up with increased demand” Assistant Director of Cloud Architecture and Engineering, manufacturer.
  • “We can shine a light in the dark corners of public cloud [with Aviatrix]” — Senior Cloud Architect, business software and services provider.
  • “With Aviatrix, we are saving millions” Assistant Director of Cloud Architecture and Engineering, manufacturer.

“We’re very pleased with the overall results of the Forrester TEI Study,” said Rod Stuhlmuller, Vice President of Product Marketing at Aviatrix. “The quantifiable data truly highlights the benefits our customers receive using the Aviatrix cloud network platform. Furthermore, our customers achieve these benefits in both single and multi-cloud environments. As more enterprises adopt a multi-cloud strategy, Aviatrix’s market leading solutions will be the foundation for demonstratable economic gains.”

Executive Summary Video of the TEI Study on Aviatrix: (5 mins)

Watch guest speaker Sean Owens, Forrester’s Principal Consultant, and leader of the TEI of Aviatrix cloud network platform study, provide an executive summary of the study’s methodology, key findings, and quantified results. View video here.

About Aviatrix

Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye